The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis - PubMed (original) (raw)
. 2013 Jul 30;8(7):e65174.
doi: 10.1371/journal.pone.0065174. Print 2013.
Goodarz Danaei, Farshad Farzadfar, Gretchen A Stevens, Mark Woodward, David Wormser, Stephen Kaptoge, Gary Whitlock, Qing Qiao, Sarah Lewington, Emanuele Di Angelantonio, Stephen Vander Hoorn, Carlene M M Lawes, Mohammed K Ali, Dariush Mozaffarian, Majid Ezzati; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group; Asia-Pacific Cohort Studies Collaboration (APCSC); Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe (DECODE); Emerging Risk Factor Collaboration (ERFC); Prospective Studies Collaboration (PSC)
Collaborators, Affiliations
- PMID: 23935815
- PMCID: PMC3728292
- DOI: 10.1371/journal.pone.0065174
The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis
Gitanjali M Singh et al. PLoS One. 2013.
Abstract
Background: The effects of systolic blood pressure (SBP), serum total cholesterol (TC), fasting plasma glucose (FPG), and body mass index (BMI) on the risk of cardiovascular diseases (CVD) have been established in epidemiological studies, but consistent estimates of effect sizes by age and sex are not available.
Methods: We reviewed large cohort pooling projects, evaluating effects of baseline or usual exposure to metabolic risks on ischemic heart disease (IHD), hypertensive heart disease (HHD), stroke, diabetes, and, as relevant selected other CVDs, after adjusting for important confounders. We pooled all data to estimate relative risks (RRs) for each risk factor and examined effect modification by age or other factors, using random effects models.
Results: Across all risk factors, an average of 123 cohorts provided data on 1.4 million individuals and 52,000 CVD events. Each metabolic risk factor was robustly related to CVD. At the baseline age of 55-64 years, the RR for 10 mmHg higher SBP was largest for HHD (2.16; 95% CI 2.09-2.24), followed by effects on both stroke subtypes (1.66; 1.39-1.98 for hemorrhagic stroke and 1.63; 1.57-1.69 for ischemic stroke). In the same age group, RRs for 1 mmol/L higher TC were 1.44 (1.29-1.61) for IHD and 1.20 (1.15-1.25) for ischemic stroke. The RRs for 5 kg/m(2) higher BMI for ages 55-64 ranged from 2.32 (2.04-2.63) for diabetes, to 1.44 (1.40-1.48) for IHD. For 1 mmol/L higher FPG, RRs in this age group were 1.18 (1.08-1.29) for IHD and 1.14 (1.01-1.29) for total stroke. For all risk factors, proportional effects declined with age, were generally consistent by sex, and differed by region in only a few age groups for certain risk factor-disease pairs.
Conclusion: Our results provide robust, comparable and precise estimates of the effects of major metabolic risk factors on CVD and diabetes by age group.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
Figure 1. Relative risks (RRs) for diseases associated with systolic blood pressure (SBP).
The figure shows RRs for 10 mmHg higher usual SBP. The figure shows RRs converted to comparable age group as described in Methods. See Table S1 for RRs in original age groups from each study. RRs for rheumatic heart disease and inflammatory heart disease apply only to deaths and those for other outcomes to deaths and incidence. The percentage of variation in the pooled estimates that is due to statistical heterogeneity was evaluated using the I2 statistic for each age group and outcome. Of all outcomes and age groups analyzed, only two age groups in the pooled analysis for hemorrhagic stroke had non-zero I2 values: I2 = 44.4% for ages 35–44 years, and I2 = 24.3% for ages 55–64 years.
Figure 2. Relative risks (RRs) for diseases associated with serum total cholesterol (TC).
The figure shows RRs for 1 mmol/L higher usual TC. The figure shows RRs converted to comparable age group as described in Methods. See Table S1 for RRs in original age groups from each study. The percentage of variation in the pooled estimates that is due to statistical heterogeneity was evaluated using the I2 statistic for each age group and outcome. Of all the outcomes and age groups analyzed, only ages 35–44 years in the pooled analysis for IHD had a non-zero I2 value of 58.8%.
Figure 3. Relative risks (RRs) for diseases associated with body mass index (BMI).
The figure shows RRs for 5 kg/m2 higher baseline BMI. The figure shows RRs converted to comparable age group as described in Methods. See Table S1 for RRs in original age groups from each study. The percentage of variation in the pooled estimates that is due to statistical heterogeneity was evaluated using the I2 statistic for each age group and outcome. Of all the outcomes and age groups analyzed, the three age groups below age 65 years in the pooled analysis for hypertensive heart disease had non-zero I2 values: 79.2% for ages 35–44 years, 69.0% for ages 45–54 years, and 37.2% for ages 55–64 years. *The associations with haemorrhagic stroke are for BMIs above 25 kg/m2 as described in text.
Figure 4. Relative risks (RRs) for diseases associated with fasting plasma glucose (FPG).
The figure shows RRs for 1 mmol/L higher usual or baseline FPG. The figure shows RRs converted to comparable age group as described in Methods. See Table S1 for RRs in original age groups from each study. The percentage of variation in the pooled estimates that is due to statistical heterogeneity was evaluated using the I2 statistic for each age group and outcome. All I2 values for these outcomes and age groups were zero.
Similar articles
- High prevalence of metabolic risk factors for cardiovascular diseases among Saudi population, aged 30-64 years.
Rahman Al-Nuaim A. Rahman Al-Nuaim A. Int J Cardiol. 1997 Dec 19;62(3):227-35. doi: 10.1016/s0167-5273(97)00268-4. Int J Cardiol. 1997. PMID: 9476683 - Association of Random Plasma Glucose Levels With the Risk for Cardiovascular Disease Among Chinese Adults Without Known Diabetes.
Bragg F, Li L, Bennett D, Guo Y, Lewington S, Bian Z, Yang L, Chen J, Chen Y, Collins R, Peto R, Zhu B, Yin J, Hu X, Zhou L, Pan Y, Chen Z; China Kadoorie Biobank (CKB) Collaborative Group. Bragg F, et al. JAMA Cardiol. 2016 Oct 1;1(7):813-823. doi: 10.1001/jamacardio.2016.1702. JAMA Cardiol. 2016. PMID: 27437922 - Body-mass index, blood pressure, diabetes and cardiovascular mortality in Cuba: prospective study of 146,556 participants.
Armas Rojas NB, Lacey B, Soni M, Charles S, Carter J, Varona-Pérez P, Burrett JA, Martínez MC, Lorenzo-Vázquez E, Constantén SB, Taylor H, Sherliker P, Rigau JMM, Ross S, Massa MS, López OJH, Islam N, Morales MÁM, Alomá IA, Estupiñan FA, González MD, Muñoz NR, Asencio MC, Díaz-Diaz O, Iglesias-Marichal I, Emberson J, Peto R, Lewington S. Armas Rojas NB, et al. BMC Public Health. 2021 May 27;21(1):963. doi: 10.1186/s12889-021-10911-9. BMC Public Health. 2021. PMID: 34039286 Free PMC article. - Prognostic interactions between cardiovascular risk factors.
Vishram JK. Vishram JK. Dan Med J. 2014 Jul;61(7):B4892. Dan Med J. 2014. PMID: 25123126 Review. - Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].
Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T. Whitlock EP, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. Report No.: 13-05193-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. Report No.: 13-05193-EF-1. PMID: 26491756 Free Books & Documents. Review.
Cited by
- Analysing premature cardiovascular disease mortality in the United States by obesity status and educational attainment.
Li H, Adair T. Li H, et al. BMC Med. 2024 Nov 14;22(1):533. doi: 10.1186/s12916-024-03752-x. BMC Med. 2024. PMID: 39543580 Free PMC article. - Disparities in high fasting plasma glucose-related cardiovascular disease burden in China.
Cao X, Tian Y, Zhao Z, Wang L, Wang X, Zheng C, Hu Z, Gu R, Yu X, Pei X, Yin P, He Y, Fang Y, Zhang M, Zhou M, Wang Z. Cao X, et al. Nat Commun. 2024 Oct 11;15(1):8817. doi: 10.1038/s41467-024-53236-y. Nat Commun. 2024. PMID: 39394204 Free PMC article. - Sociodemographic and Clinical Predictors of Weight Gain During the First Year of Antiretroviral Therapy among Adults Living With HIV in Urban Tanzania.
Chillo P, Muhihi A, Danaei G, Bakari M, Kwesigabo G, Njelekela M, Ulenga N, Fawzi WW, Mugusi F, Sudfeld CR. Chillo P, et al. J Int Assoc Provid AIDS Care. 2024 Jan-Dec;23:23259582241281010. doi: 10.1177/23259582241281010. J Int Assoc Provid AIDS Care. 2024. PMID: 39360426 Free PMC article. - Association of obesity severity and duration with incidence of chronic kidney disease.
Ghazy F, Ebrahimi N, Ebadinejad A, Barzin M, Mahdavi M, Valizadeh M, Azizi F, Hosseinpanah F. Ghazy F, et al. BMC Nephrol. 2024 Sep 27;25(1):320. doi: 10.1186/s12882-024-03757-x. BMC Nephrol. 2024. PMID: 39333911 Free PMC article. - 2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part I.
Chao TH, Lin TH, Cheng CI, Wu YW, Ueng KC, Wu YJ, Lin WW, Leu HB, Cheng HM, Huang CC, Wu CC, Lin CF, Chang WT, Pan WH, Chen PR, Ting KH, Su CH, Chu CS, Chien KL, Yen HW, Wang YC, Su TC, Liu PY, Chang HY, Chen PW, Juang JJ, Lu YW, Lin PL, Wang CP, Ko YS, Chiang CE, Hou CJ, Wang TD, Lin YH, Huang PH, Chen WJ. Chao TH, et al. Acta Cardiol Sin. 2024 Sep;40(5):479-543. doi: 10.6515/ACS.202409_40(5).20240724A. Acta Cardiol Sin. 2024. PMID: 39308649 Free PMC article.
References
- Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ (2002) Selected major risk factors and global and regional burden of disease. Lancet 360: 1347–1360. - PubMed
- James WPT, Jackson-Leach R, Ni Mhurchu C, Kalamara E, Shayeghi M, et al... (2004) Overweight and obesity (high body mass index). In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, editors. Comparative quantification of health risks. Geneva: World Health Organization. pp. 497–596.
- Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, et al... (2004) High Blood Pressure. In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, editors. Comparative quantification of health risks. Geneva: World Health Organization. pp. 497–596.
Publication types
MeSH terms
Substances
Grants and funding
- G19/35/MRC_/Medical Research Council/United Kingdom
- P30 ES005605/ES/NIEHS NIH HHS/United States
- RG/08/014/24067/BHF_/British Heart Foundation/United Kingdom
- G1000616/MRC_/Medical Research Council/United Kingdom
- G0401527/MRC_/Medical Research Council/United Kingdom
- T32 DK007703/DK/NIDDK NIH HHS/United States
- MR/K005901/1/MRC_/Medical Research Council/United Kingdom
- RG/07/008/23674/BHF_/British Heart Foundation/United Kingdom
- G0100222/MRC_/Medical Research Council/United Kingdom
- DK007703/DK/NIDDK NIH HHS/United States
- G8802774/MRC_/Medical Research Council/United Kingdom
- G1000143/MRC_/Medical Research Council/United Kingdom
- RG/08/013/25942/BHF_/British Heart Foundation/United Kingdom
- G0902037/MRC_/Medical Research Council/United Kingdom
- MC_U137686857/MRC_/Medical Research Council/United Kingdom
- MR/L003120/1/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical